MedeliX
Start asking

faricimab

Vabysmo · ATC code S01LA09

Also known as: Farisimab

Key facts
Active substance
faricimab
ATC code
S01LA09
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
Vabysmo 120 mg/mL solution for injection / Vabysmo 120 mg/mL solution for injection in pre-filled syringe
Marketing authorisation holder
Roche Registration GmbH
Information as of
2026-10-28

Key facts

Faricimab is a bispecific antibody against angiopoietin-2 and VEGF-A, given by intravitreal injection to treat wet age-related macular degeneration and macular oedema (Vabysmo).

What it is used for

  • Neovascular (wet) age-related macular degeneration (nAMD) in adults.
  • Visual impairment due to diabetic macular oedema (DME).
  • Visual impairment due to macular oedema secondary to retinal vein occlusion (branch or central RVO).

Dosing

  • nAMD: 6 mg (0.05 mL) intravitreally every 4 weeks for the first 3 doses; assess disease activity at 16 and/or 20 weeks, then every 8, 12 or 16 weeks depending on activity.
  • DME and RVO: 6 mg (0.05 mL) intravitreally every 4 weeks; 3 or more consecutive monthly injections may be needed, then individualised extension in increments of up to 4 weeks (treat-and-extend).
  • Only by a qualified physician experienced in intravitreal injections.
  • When switching from other anti-VEGF therapies, intervals are set by the physician's judgement; details: see the full text.

Contraindications

  • Hypersensitivity to the active substance or any excipient.
  • Active or suspected ocular or periocular infections.
  • Active intraocular inflammation.

Important warnings

  • Injection-related reactions such as endophthalmitis, intraocular inflammation, retinal detachment, retinal tear and traumatic cataract; use aseptic technique; patients should report pain, vision loss or redness without delay.
  • Transient intraocular pressure increases within 60 minutes; do not inject while IOP is ≥ 30 mmHg.
  • Theoretical risk of systemic events including arterial thromboembolic events.
  • Limited data on treating both eyes concurrently.

Side effects

  • Most frequent: cataract (10%), conjunctival haemorrhage (7%), vitreous detachment (4%), IOP increased (4%), vitreous floaters (4%), eye pain (3%) and retinal pigment epithelial tear (nAMD only, 3%).
  • Most serious: uveitis (0.5%), endophthalmitis (0.4%), vitritis (0.4%), retinal tear (0.2%), rhegmatogenous retinal detachment (0.1%) and traumatic cataract (< 0.1%).

Interactions

  • No interaction studies; should not be given concurrently with other systemic or ocular anti-VEGF medicines.

Pregnancy and breastfeeding

  • Women of childbearing potential should use effective contraception during treatment and for at least 3 months after the last injection; use in pregnancy only if the benefit outweighs the risk.
  • Should not be used during breast-feeding.

Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

  • VabysmoRoche Registration GmbH · EMEA/H/C/005642

Source: European Medicines Agency (EMA), product information

Turkey

  • VabysmoROCHE MÜSTAHZARLARI SAN.A.Ş. · 1 register entry

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 3 more European countries
Iceland
Vabysmo
Liechtenstein
Vabysmo
Norway
Vabysmo

EMA – Article 57 product data (EU/EEA), 2026-10-29

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Vabysmo – EPAR, Product Information. 2026-10-28. https://www.ema.europa.eu/en/documents/product-information/vabysmo-epar-product-information_en.pdf
  2. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85

Editorial: Medelix editorial team · last updated 2026-10-28 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.